Skip to main content
. 2019 May 21;8(8):3677–3684. doi: 10.1002/cam4.2238

Table 1.

Baseline population characteristics

Characteristics FIGHTDIGO Population (n=201) Patients with at least one assessable CT scan (n=150) No assessable CT scan (n=51) Univariate Analysis P value
Age, mean ± SD 65.5 ± 10.8 65.6 ± 10.9 65.1 ± 10.8 0.80
Gender, N (%)       0.92
Men 117 (58.2) 87 (58.0) 30 (58.8)  
Women 82 (41.8) 63 (42.0) 21 (41.2)  
BMI, mean ±SD 25.0 ± 5.1 24.9 ± 4.9 25.3 ± 5.5 0.56
Leg edema, N (%) 4 (2.0) 4 (2.7) 0 (0.0) 0.57
Serum albumin, mean ±SD 38.6 ± 4.5 38.4 ± 4.6 39.4 ± 4.1 0.15
C‐reactive protein, mean ±SD 15.9 ± 32.8 17.8 ± 37.1 11.1 ± 15.5 0.09
Previous oncologic surgery, N (%) 128 (63.7) 87 (58.0) 41 (80.4) 0.004
mGPS, N (%)       0.29
0 99 (55.0) 68 (51.5) 31 (64.6)  
1 68 (37.8) 54 (40.9) 14 (29.2)  
2 13 (7.2) 10 (7.6) 2 (6.2)  
G8 score, mean ± SD 12.4 ± 2.1 12.1 ± 2.6 13.2 ± 2.2 0.12
Primary tumor, N (%)       0.35
Colon and rectum 103 (51.2) 71 (47.3) 32 (62.7)  
Oesphagus 8 (4.0) 5 (3.3) 3 (5.9)  
Stomach 22 (10.9) 16 (10.7) 6 (11.8)  
Cholangiocarcinoma 11 (5.5) 9 (6.0) 2 (3.9)  
Pancreas 44 (21.9) 38 (25.3) 6 (11.8)  
Small intestine 3 (1.5) 2 (1.3) 1 (2.0)  
Neuroendocrine tumor 8 (4.0) 7 (4.7) 1 (2.0)  
Adenocarcinoma, unknown primitive tumor 2 (1.0) 2 (1.3) 0 (0.0)  
Stage, N (%)       <0.0001
Local 40 (19.9) 19 (12.7) 19 (41.2)  
Locally advanced 23 (11.4) 16 (10.7) 7 (13.7)  
Metastatic 138 (68.7) 115 (76.7) 23 (45.1)  
Type of treatment, N (%)       0.004
Chemotherapy alone 147 (73.1) 101 (67.3) 46 (90.2)  
Biotherapy alone 4 (2.0) 4 (2.7) 0 (0.0)  
Chemotherapy and biotherapy 50 (24.9) 45 (30.0) 5 (9.8)  
Indication, N (%)       <0.0001
Adjuvant 47 (23.4) 23 (15.3) 24 (47.1)  
Neoadjuvant 10 (5.0) 7 (4.7) 3 (5.9)  
Palliative 144 (71.6) 120 (80.0) 24 (47.1)  
First line, N (%) 132 (65.2) 92 (61.3) 40 (78.4) 0.03

Abbreviations: BMI, body mass index; mGPS, modified Glasgow Prognostic Score; N, number; SD, standard deviation.